Artwork

Contenido proporcionado por The Center for Investigative Reporting and PRX, The Center for Investigative Reporting, and PRX. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente The Center for Investigative Reporting and PRX, The Center for Investigative Reporting, and PRX o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
Player FM : aplicación de podcast
¡Desconecta con la aplicación Player FM !

America Goes Psychedelic, Again

50:50
 
Compartir
 

Manage episode 381154577 series 44456
Contenido proporcionado por The Center for Investigative Reporting and PRX, The Center for Investigative Reporting, and PRX. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente The Center for Investigative Reporting and PRX, The Center for Investigative Reporting, and PRX o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.

Psychedelic drugs have been illegal for 50 years, but they’re trickling back into the mainstream because they show promise in helping treat post-traumatic stress disorder and other mental health challenges.

We begin the hour with reporter Jonathan A. Davis visiting Psychedelic Science 2023, the largest-ever conference on psychedelic drugs. It’s put on by the Multidisciplinary Association for Psychedelic Studies, an organization dedicated to legalizing MDMA (also known as ecstasy or molly) and other psychedelic drugs. Research shows that MDMA-assisted therapy can help treat depression and PTSD, and it’s moving toward approval by the U.S. Food and Drug Administration. Psychedelics were studied in the 1950s and ’60s as mental health treatments, but the war on drugs put a stop to research. Now, these drugs are gaining bipartisan support from politicians looking for solutions to the mental health crisis among veterans.

Then Reveal’s Michael I Schiller visits a group of veterans who are not waiting for psychedelic-assisted therapy to be approved by the federal government. They’ve joined a church founded by an Iraq War veteran who uses psychedelics as religious sacraments. Schiller accompanies them on a retreat in rural Texas, where they share the depths of their post-traumatic stress and the relief they’ve felt after psychedelic treatments. He also explores the risks involved in taking these drugs.

We close with an intimate audio diary from a woman in Oakland, California, who’s going through therapy with the one psychedelic drug that can be legally prescribed currently in the U.S.: ketamine. Ketamine started out as an anesthetic, but researchers found it can help with treatment-resistant depression when used in tandem with talk therapy. Ketamine can be dangerous if abused, but it also has helped people find relief from mental health issues. This story was produced by Davis.

  continue reading

564 episodios

Artwork

America Goes Psychedelic, Again

Reveal

125,086 subscribers

published

iconCompartir
 
Manage episode 381154577 series 44456
Contenido proporcionado por The Center for Investigative Reporting and PRX, The Center for Investigative Reporting, and PRX. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente The Center for Investigative Reporting and PRX, The Center for Investigative Reporting, and PRX o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.

Psychedelic drugs have been illegal for 50 years, but they’re trickling back into the mainstream because they show promise in helping treat post-traumatic stress disorder and other mental health challenges.

We begin the hour with reporter Jonathan A. Davis visiting Psychedelic Science 2023, the largest-ever conference on psychedelic drugs. It’s put on by the Multidisciplinary Association for Psychedelic Studies, an organization dedicated to legalizing MDMA (also known as ecstasy or molly) and other psychedelic drugs. Research shows that MDMA-assisted therapy can help treat depression and PTSD, and it’s moving toward approval by the U.S. Food and Drug Administration. Psychedelics were studied in the 1950s and ’60s as mental health treatments, but the war on drugs put a stop to research. Now, these drugs are gaining bipartisan support from politicians looking for solutions to the mental health crisis among veterans.

Then Reveal’s Michael I Schiller visits a group of veterans who are not waiting for psychedelic-assisted therapy to be approved by the federal government. They’ve joined a church founded by an Iraq War veteran who uses psychedelics as religious sacraments. Schiller accompanies them on a retreat in rural Texas, where they share the depths of their post-traumatic stress and the relief they’ve felt after psychedelic treatments. He also explores the risks involved in taking these drugs.

We close with an intimate audio diary from a woman in Oakland, California, who’s going through therapy with the one psychedelic drug that can be legally prescribed currently in the U.S.: ketamine. Ketamine started out as an anesthetic, but researchers found it can help with treatment-resistant depression when used in tandem with talk therapy. Ketamine can be dangerous if abused, but it also has helped people find relief from mental health issues. This story was produced by Davis.

  continue reading

564 episodios

Todos los episodios

×
 
Loading …

Bienvenido a Player FM!

Player FM está escaneando la web en busca de podcasts de alta calidad para que los disfrutes en este momento. Es la mejor aplicación de podcast y funciona en Android, iPhone y la web. Regístrate para sincronizar suscripciones a través de dispositivos.

 

Guia de referencia rapida